TB-500 (5mg/10mg)

What is TB-500 (Thymosin Beta-4)?

TB-500 is a catalog name used for thymosin-beta-4-related research materials. This catalog lists 5mg and 10mg vials. The name alone does not establish the supplied peptide's exact sequence.

Listed vial contents: 5mg / 10mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

Which identity should I verify?

The exact supplied construct remains unconfirmed. Full-length thymosin beta-4 and the Ac-LKKTETQ fragment are distinct. Match sequence, molecular weight and analytical identity to the original lot document; do not use the catalog's parent-peptide CAS or mass as confirmation.

What mechanisms are being studied?

Full-length thymosin beta-4 interacts with actin, a protein involved in cell structure and movement. Researchers examine its role in cell migration and tissue responses. Those findings must not automatically be attributed to a different fragment.

What are the research questions?

• Actin-associated cell behavior
• Cell migration and tissue-response models
• Comparing full-length thymosin beta-4 with defined fragments

What does the published work describe?

Malinda and colleagues' 1999 paper studied wound healing with thymosin beta-4 in a preclinical model. Goldstein and colleagues' 2012 review discusses the parent peptide's properties and clinical research context. Neither reference establishes equivalence between full-length thymosin beta-4 and an unspecified product labelled TB-500. Esposito and colleagues' 2012 analytical paper identified an N-terminal acetylated fragment in material labelled TB-500. That finding illustrates why sequence verification matters; it does not identify this inventory.

What could future research explore?

Thymosin-beta-4 research raises questions about tissue repair and formulation-specific applications. Future work must identify the tested construct and distinguish parent-peptide findings from fragment findings before comparing results.

These are research directions, not established applications of the product sold here.

What are the limits of this evidence?

Evidence for the full-length parent peptide is not evidence for every TB-500-labelled material. Neither a catalog name nor a study of another formulation establishes the effectiveness, safety or analytical identity of this vial.

Study references

1. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. PMID 10469335
2. Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. PMID 22074294
3. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500. Drug Test Anal. 2012. PMID 22529068

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. Generated sample reports illustrate the reporting flow and are not evidence of testing, purity or accreditation.